Fulgent Genetics (NASDAQ: FLGT) saw a surge in shares by over 8% despite a grim day for the stock market. The company’s second-quarter revenue hit nearly $82 million, a 15% increase from last year. Analysts had predicted a loss of $0.18 per share, but Fulgent reported an adjusted net loss of only $0.07 per share.

The company credited diversification for its success, highlighting growth in laboratory services and clinical trials. Fulgent raised its full-year 2025 revenue guidance to approximately $320 million, exceeding analyst expectations. Adjusted net loss is forecasted at $0.35 per share, compared to the projected $0.55 per share loss.

Fulgent Genetics made it to the Motley Fool’s list of 10 best stocks to buy now. The expert analyst team, boasting a 1,036% average return, recommended the company. Fulgent’s potential was recognized for its recent earnings report and growth prospects in the genetic testing industry.

Read more at Yahoo Finance: Why Fulgent Genetics Stock Was Crushing It on Friday